Format

Send to

Choose Destination
Biochem Biophys Res Commun. 2009 Nov 20;389(3):490-4. doi: 10.1016/j.bbrc.2009.09.007. Epub 2009 Sep 6.

Identification and characterization of novel TRPV4 modulators.

Author information

1
In Vitro Pharmacology Department, Renovis, Inc., South San Francisco, CA 94080, USA. fabien.vincent@evotec.com

Abstract

TRPV4, a close relative of the vanilloid receptor TRPV1, is activated by diverse modalities such as endogenous lipid ligands, hypotonicity, protein kinases and, possibly, mechanical inputs. While its multiple roles in vivo are being explored with KO mice and selective agonists, there is a dearth of selective antagonists available to examine TRPV4 function. Herein we detail the use of a focused library of commercial compounds in order to identify RN-1747 and RN-1734, a pair of structurally related small molecules endowed with TRPV4 agonist and antagonist properties, respectively. Their activities against human, rat and mouse TRPV4 were characterized using electrophysiology and intracellular calcium influx. Significantly, antagonist RN-1734 was observed to completely inhibit both ligand- and hypotonicity-activated TRPV4. In addition, RN-1734 was found to be selective for TRPV4 in a TRP selectivity panel including TRPV1, TRPV3 and TRPM8, and could thus be a valuable pharmacological probe for TRPV4 studies.

PMID:
19737537
DOI:
10.1016/j.bbrc.2009.09.007
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center